Pharmacokinetic interactions of statins

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 23, Issue 10, 2001, Pages 541-566

  Reinoso, R F ^a   Navarro, A Sánchez ^a   Garcia M J ^a   Prous, J R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

Drug drug interactions; HMG CoA reductase inhibitors; Pharmacokinetics; Statins

Indexed keywords

CILOSTAZOL; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DIAZEPAM; DICLOFENAC; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUCONAZOLE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISRADIPINE; KETOCONAZOLE; LACIDIPINE; LOSARTAN; MIBEFRADIL; NELFINAVIR; NIFEDIPINE; RIFAMPICIN; SILDENAFIL; STATINE DERIVATIVE; TACROLIMUS; TERFENADINE; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; FOOD DRUG INTERACTION; HUMAN; NONHUMAN; REVIEW;

EID: 0035569260     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2001.23.10.677120     Document Type: Review

References (141)

1. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
2. ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems
3. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human
4. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
5. An evaluation of CYP3A4 drug interactions with HMG-CoA reductase inhibitors
6. HMG-CoA reductase inhibitors and P-glycoprotein modulation
7. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation
8. The physiological function of drug-transporting P-glycoproteins
9. Intestinal secretion of drugs: The role of P-glycoprotein and related drug efflux system in limiting oral drug absorption
10. The contribution of P-glycoprotein to pharmacokinetic drug-drug-interactions
11. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
12. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles
13. New insights into the pharmacodynamic and pharmacokinetic properties of statins
14. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors
15. Rhabdomyolysis and HMG-CoA reductase inhibitors
16. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
17. Drug interactions of the statins and consequences for drug selection
18. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
19. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
20. Clinical pharmacokinetics of fluvastatin
21. Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events
22. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects
23. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier
24. Clinical pharmacokinetics of cerivastatin
25. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening
26. Effect of food on pravastatin pharmacokinetics and pharmacodynamics
27. Fluvastatin administration at bedtime versus with the evening meal: A multicenter comparison of bioavailability safety, and efficacy
28. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor
29. Atorvastatin (CI-981) clinical pharmacokinetic study (III) - Effect of food on bioavailability of atorvastatin
30. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase
31. Pharmacokinetics of fluvastatin and specific drug interactions
32. Clinical implications of the biopharmaceutical properties of fluvastatin
33. Lovastatin and other HMG-CoA reductase inhibitors
34. Drug interactions with grapefruit juice
35. Grapefruit juice-drug interactions
36. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
37. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
38. Grapefruit juice increases serum simvastatin and atorvastatin but not pravastatin
39. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
40. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
41. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
42. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function
43. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin
44. Alcohol and the risk of myocardial infarction
45. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
46. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
47. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
48. Effect of itraconazole on the pharmacokinetics of atorvastatin
49. Itroconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
50. Effect of itraconazole on cerivastatin pharmacokinetics
51. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
52. Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects
53. The interaction of diltiazem with simvastatin
54. The interaction of diltiazem with lovastatin and pravastatin
55. Oral but not intravenous (iv) diltiazem impairs lovastatin clearance
56. Intravenous diltiazem and CYP3A-mediated metabolism
57. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients
58. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
59. In vitro and in vivo metabolism of atorvastatin (CI-981)
60. Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers
61. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects
62. Rhabdomyolysis due to interaction of simvastatin with mibefradil
63. Mibefradil significantly increases serum concentrations of atorvastatin but not provastatin
64. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics
65. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information
66. Lack of drug-drug interaction between cerivastatin and nifedipine
67. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
68. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects
69. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin
70. Pharmacokinetic interactions between nelfinavir and two HMG-CoA inhibitors simvastatin and atorvastatin
71. Erythromycin coadministration increases plasma atorvastatin concentrations
72. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
73. Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study
74. Atorvastatin pharmacokinetic interactions with other CYP 3A4 substrates: Erythromycin and ethinyl estradiol
75. Minor alterations in cerivastatin pharmacokinetics by erythromycin and itraconazole
76. Pharmacokinetic interaction between roxithromycin and lovastatin in volunteers
77. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy
78. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin
79. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin
80. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy
81. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia
82. Influence of cholestyramine on the pharmacokinetics of cerivastatin
83. SCH-58235 does not affect the pharmacokinetics of simvastatin
84. No pharmacokinetic drug interaction between ezetimibe and lovastatin
85. Statin-fibrate combination therapy
86. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
87. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
88. Drug interactions with fibric acids
89. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
90. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
91. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
92. Pharmacokinetics of the combination of fluvastatin and gemfibrozil
93. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction
94. Influence of the antiacid Maalox® and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin
95. No drug-drug interaction between cerivastatin and omeprazole
96. The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man
97. Effects of Maalox TC on pharmacokinetics and pharmacodynamics of atorvastatin
98. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are statins mechanistically similar?
99. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin
100. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients
101. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporin
102. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporin-treated kidney graft patients after multiple doses
103. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant patients
104. Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system
105. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporin-treated kidney transplant recipients
106. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
107. Tacrolimus/cerivastatin interaction study in liver transplant recipients
108. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers
109. Steady state serum concentrations of pravastatin and digoxin when given in combination
110. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers
111. Effect of troglitazone on PK and PD of atorvastatin
112. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects
113. A drug interaction between troglitazone and simvastatin
114. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with noninsulin-dependent diabetes mellitus
115. Lack of effect of orlistat on the pharmacokinetics and pharmacodynamics of pravastatin
116. Lack of pharmacokinetic drug-drug interaction, between orlistat and cerivastatin
117. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors
118. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
119. Lack of a drug interaction between sildenafil and atorvastatin
120. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin
121. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
122. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine
123. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine
124. The interaction of fluvastatin and cyclosporin A in renal transplant patients
125. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin
126. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin
127. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
128. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
129. Inhibitory effect of fluconazole (FLC) and erythromycin (ERY) plus fluvastatin (FLV) on losartan (L) disposition in normal volunteers
130. How well tolerated are lipid-lowering drugs?
131. Effect if simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients
132. Lack of interaction between ramipril and simvastatin
133. Simvastatin-oral anticoagulant interaction
134. Simvastatin during warfarin therapy in hyper lipoproteinaemia
135. Clinical pharmacokinetics and practical applications of simvastatin